PRRT2 and cancer: A growing body of research has shown that the activation of the PKC/Nox signaling complex regulates ROS levels and is involved in various pathophysiological conditions, including neurodegenerative disorders [105,106], human cardiovascular disease, such as atherosclerosis [95,107–111], hypertension [112,113], renal damage [91], diabetes [114–117], and cancer [118].